| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Analysis Of The Success And Failure Of Doing Business In China |
|
Main Subject - Analysis Of The Success And Failure Of Doing Business In China
Why some foreign-funded enterprise became successful when entering the China market while others fail, and why some grow relat According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ively faster than the rest? Reasons to explain all these are complex and varied. The following factors can determine how well ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in or bad foreign-funded enterprise fare in China: 1. Establishment and implementation of enterprise's development strategy. In lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. China, successful MNCs and foreign-funded enterprise will definitely implement long-term development strategy, adopting a long here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe term outlook for their business, unlike other unsuccessful companies which do not look far and only concentrate on short-term d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro gains. Besides adopting a development strategy that is of long time horizon, the strategy will need to be a flexible one as ma ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc rket conditions are constantly changing due to the presence of globalization. The enterprise need to be flexible as to react i easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi mediately to any changes without affecting its business operations. 2. Leadership of the top management plays a decisive role nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically in deciding the success of the company. In face of greater competition brought about by globalization, management today will and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ need to possess stronger judgment, decision ability, adaptability and greater foresight. Ability to look far is crucial as one ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi need to be able to foresee unforeseen circumstances in order to be ready at all times to react to any changes. 3. Form key co ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a mpetitiveness for the enterprise, and grow together with the economy. Treat your staff with an open heart, cultivate the enter dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod prise’s values and vision constantly into them to foster togetherness within the organization and strengthen the organization’ cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin s strengths. . 4. Build and strengthen the institutional framework and economic system of the enterprise. MNCs usually will tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen stablish main or Asian headquarters in key cities in China. Beside that, research and development centre, training centre and t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel logistic base will also be built. Therefore it is vital for the organization to have a strong organization structure dealing w ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ith its cash flow, flow of information and manpower movement in order to ensure its success in China 5. It is essential for t y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products e foreign-funded enterprises to understand the China’s culture, especially regarding the culture of Guangxi (relationship), so . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de as to be able to gain the popularity and trust of China population. With a good relationship, business can become smoother a elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip nd probability of failure will be greatly reduced. Stronger bonds can also be built with the customers, suppliers and partners tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Making an Agreement with Your Power Team Corporate America vs. Work/Life Balance Unlocking Mark Burnett's Secrets of Success
|